Sermorelinsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Sermorelin as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Sermorelin is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Sermorelin has the largest published clinical-trial safety dataset of any GHRH-analogue compound, accumulated during the Geref clinical-development programme and post-marketing surveillance. The acute adverse-event profile is mild: injection-site reactions (erythema, transient pain, occasional itching) are the most common; mild transient flushing, headache, and brief warmth following injection are reported; occasional nausea and dysgeusia at higher doses; no clinically significant changes in routine haematology, biochemistry, or vital signs at therapeutic dose ranges. Anti-sermorelin antibodies have been reported with chronic dosing but did not produce clinically significant loss of efficacy in published trials. The chronic-dosing safety profile is correspondingly better-characterised than other GH-axis peptides. In paediatric GH-deficiency therapeutic use during the Geref era, multi-year dosing produced no signal of increased malignancy, no accelerated cardiovascular events, and no documented immune dysregulation. Insulin resistance with chronic dosing was noted but to a milder degree than chronic recombinant somatropin — reflecting the pulsatile-preserving release pattern. Diabetic retinopathy progression was monitored as a theoretical concern but did not emerge as a significant clinical issue. The theoretical concerns common to GH-axis peptides apply: chronic supraphysiological IGF-1 elevation theoretically carries oncogenic risk; insulin resistance with sustained GH/IGF-1 elevation is a recognised complication; diabetic retinopathy progression should be monitored in susceptible individuals. The pulsatile-pattern preservation of sermorelin protocols substantially mitigates the GH-receptor-desensitisation and IGF-1-receptor-downregulation concerns that affect chronic recombinant somatropin or sustained-release DAC-variant CJC-1295. Sermorelin's 29-amino-acid native sequence carries some immunogenicity risk; anti-drug antibodies with chronic dosing have been characterised in published work, but generally do not produce clinically significant loss of efficacy. The compound's natural-sequence identity also means cross-reactivity with native GHRH antibodies is theoretically possible, though not a documented clinical issue. No serious acute adverse events (anaphylaxis, severe hypotension, cardiac events) have been reported at research-protocol doses. The overall safety record is the most favourable of the GH-axis peptide class given the depth of clinical experience.

UK regulatory status

Sermorelin is not currently authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) following the global discontinuation of the Geref product in 2008. It holds no current marketing authorisation in any major jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Sermorelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone-releasing hormone analogue. Athletes subject to anti-doping testing should treat sermorelin and all GHRH-analogue compounds as prohibited both in-competition and out-of-competition regardless of claimed research purpose. MHRA enforcement actions concerning sermorelin supply specifically have not been published in the public domain. Generic warnings on unlicensed peptide supply for human use apply. Research-grade sermorelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. The compound's historical FDA-approved status (Geref, 1990-2008) does not confer current UK marketing authorisation. For animal research under ASPA (Animals (Scientific Procedures) Act 1986), sermorelin work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Sermorelin is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Sermorelin research context including mechanism, study citations, and references, see the main Sermorelin research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.